Particle.news
Download on the App Store

Investors Weigh Intuitive Surgical’s Growth Against Medtronic’s Value in Robotic Surgery

The choice turns on appetite for valuation risk versus income-focused exposure to surgical robotics.

Overview

  • Intuitive Surgical remains the category leader with more than 9,900 da Vinci systems installed across 72 countries and over 16 million procedures performed.
  • Only about a quarter of Intuitive’s revenue comes from system sales, with the majority generated by recurring instruments, accessories, and service.
  • In Q3 2025, Intuitive reported $2.5 billion in revenue, including $1.5 billion from instruments and accessories, $590 million from systems, and $396 million from services, with GAAP net income rising 24% to $709 million.
  • Intuitive’s shares jumped 23% last month after strong results, and the stock trades at a forward P/E of about 59, above its five-year average of 56.
  • Medtronic, which is expanding in robotic surgery, offers a recent forward P/E near 18 and a dividend yield around 2.8%, and it reported a solid quarter through Oct. 24 with revenue and EPS exceeding expectations.